Top 2 Health Care Stocks You May Want To Dump This Month

Two health-care names are flagged as technically overbought heading into Dec. 2, 2025: Exact Sciences (EXAS) and Haemonetics (HAE) each have RSIs near 90, well above the 70 overbought threshold. Abbott agreed on Nov. 20 to buy Exact Sciences for $105 per share, implying roughly $21 billion equity and $23 billion enterprise value; EXAS has rallied about 51% over the past month and closed at $101.20 (52-week high $101.87). Haemonetics reported Q2 EPS of $1.27 vs. $1.11 consensus and revenue $327.316M vs. $311.399M, raised FY2026 EPS guidance, and has gained ~61% over the past month, closing at $80.96 (52-week high $88.31). The combination of deal-driven and fundamental catalysts has driven sharp short-term rallies, but extreme RSI readings suggest elevated risk of momentum reversal.

Analysis

Market structure: ABT's announced acquisition of EXAS (deal price $105) directly benefits EXAS shareholders and Abbott's strategic positioning in oncology diagnostics while removing a high-growth public comparables from the investable universe; competing diagnostics players (e.g., Guardant-type assets) face both competitive pressure and a higher M&A valuation floor, compressing the supply of cheap targets and lifting takeover premia by several hundred basis points in the mid-cap diagnostics cohort over the next 6–12 months. Cross-asset: expect elevated equity IV and put-call skew in EXAS/HAE, modest widening of high-yield spreads for small med-tech issuers if M&A picks up, and short-term USD bid for acquirers funding deals with debt issuance.

Risk assessment: near-term tail risks include deal failure (regulatory antitrust, material adverse discovery) for EXAS and order/book weakness or reimbursement changes for HAE; probability low-to-moderate but P&L asymmetric given EXAS’s ~3.6% gap to the $105 offer and HAE’s >60% one-month run. Time horizons: days—RSI>89 signals likely mean reversion; weeks–months—HAE will be priced on FY2026 delivery and next quarterly cadence; 3–9 months—typical M&A close window for EXAS. Key hidden dependency: payer/reimbursement revisions and integration capex can erode projected synergies.

trade implications: avoid initiating unhedged momentum longs in EXAS/HAE; tactical plays include small-sized merger-arb exposure to EXAS (targeting capture of the ~$3.80 spread to $105 with strict spread stops) and volatility-defined bearish option structures on HAE to monetize RSI reversion while limiting gamma risk. Sector rotation: reduce small/mid-cap diagnostic/med-tech momentum exposure by 1–3% of portfolio and redeploy into large-cap diversified healthcare (e.g., ABT, JNJ) and selected healthcare defensives with lower sensitivity to flow unwinds over the next 4–12 weeks.

contrarian angles: consensus treats both moves as pure momentum—misses that EXAS removal from public comps may structurally raise multiples for remaining names, supporting longer-term valuations even as short-term mean reversion occurs. The reaction may be overdone in HAE: a 60% one-month move typically precedes a 10–25% pullback within 30 days historically for similarly liquid med-techs, creating defined downside buying windows. Unintended consequence: forced outflows from quant/momentum funds could create transient dislocations—look to buy IV after a 20%+ intraday slide or on volume-driven capitulation.

Key Decisions for Investors

• Establish a 1–2% merger-arbitrage long position in EXAS at current market (~$101.20) targeting the $105 deal consideration; size conservatively, set a hard stop if spread widens to >7% (i.e., EXAS < $97.65) or if ABT announces financing/regulatory complications. Expect a 3–9 month time horizon to close; hedge tail risk by buying a 6–9 month $95 EXAS put for ~0.5% portfolio exposure if available.
• Initiate a bearish, capped-risk options position on HAE to exploit RSI mean reversion: buy a 2-month 75/70 put debit spread sized 0.5–1% of portfolio (risk defined) and add to 1.5–2% size only if HAE trades below $72 on volume. Cover/close if HAE holds >$88 for two consecutive weeks or on the next quarterly report if revenue guidance materially accelerates.
• Rotate 1–3% of portfolio out of small/mid-cap diagnostics/med-tech momentum names into large-cap diversified healthcare: establish 1–2% long in ABT and 1% long in JNJ (or equivalent) over the next 1–4 weeks to capture defensive cash flows and M&A synergies while volatility contracts in EXAS/HAE.
• For existing longs in EXAS/HAE: sell 30–45 day covered calls 5–7% out-of-the-money to harvest IV premium and reduce net exposure; avoid adding naked exposure until RSI falls below 70 or IV compresses by at least 30% from current levels.